Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBIT (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBIT for 5 consecutive years, with -$15.2 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 29.68% to -$15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$59.1 million through Dec 2025, up 34.76% year-over-year, with the annual reading at -$59.1 million for FY2025, 34.76% up from the prior year.
  • EBIT hit -$15.2 million in Q4 2025 for Kezar Life Sciences, down from -$11.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.7 million in Q3 2025 to a low of -$34.6 million in Q4 2023.
  • Historically, EBIT has averaged -$19.3 million across 5 years, with a median of -$18.3 million in 2022.
  • Biggest five-year swings in EBIT: crashed 72.65% in 2023 and later skyrocketed 46.62% in 2025.
  • Year by year, EBIT stood at -$14.1 million in 2021, then plummeted by 42.05% to -$20.0 million in 2022, then plummeted by 72.65% to -$34.6 million in 2023, then surged by 37.66% to -$21.6 million in 2024, then increased by 29.68% to -$15.2 million in 2025.
  • Business Quant data shows EBIT for KZR at -$15.2 million in Q4 2025, -$11.7 million in Q3 2025, and -$14.6 million in Q2 2025.